New drug shows promise for rare muscle diseases

NCT ID NCT06698796

Recruiting now Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis, rare diseases that cause muscle weakness and rashes. Participants who completed a previous study can join. Some will receive the drug via IV every 4 weeks for about a year, while others will only have safety check-ups. The goal is to see if dazukibart can help control symptoms over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dazukibart (a drug given as an IV infusion every 4 weeks)
What this could lead to: If successful, this could provide a long-term treatment option to control muscle inflammation and improve daily function for people with dermatomyositis or polymyositis.
What could go wrong: This is an extension study, so it builds on earlier results. However, it is still testing safety and efficacy, and not all participants will receive the drug. Side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired idiopathic inflammatory myopathy dermatomyositis polymyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS POLYMYOSITIS

Contacts and locations

Locations

AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale
RECRUITING

Glendale, Arizona, 85306, United States
Anhui Provincial Hospital
RECRUITING

Hefei, Anhui, 230071, China
Arthritis & Rheumatology Research Institute, PLLC
NOT_YET_RECRUITING

Allen, Texas, 75013, United States
CHARM HEALTHCARE PRIVATE LIMITED (Previously Dr Shenoy's Care Private Limited)
RECRUITING

Ernākulam, Kerala, 682040, India
Centro de Investigaciones Médicas Tucuman
RECRUITING

SAN M. de Tucuman, Tucumán Province, T4000AXL, Argentina
Chi Mei Medical Center
NOT_YET_RECRUITING

Tainan, 71004, Taiwan
Cryptex Investigación Clínica S.A. de C.V.
RECRUITING

Cuauhtémoc, Mexico City, 06100, Mexico
Debreceni Egyetem Klinikai Kozpont
RECRUITING

Debrecen, 4032, Hungary
First Affiliated Hospital of Kunming Medical University
RECRUITING

Kunming, Yunnan, 650032, China
Hacettepe Universite Hastaneleri
RECRUITING

Altindağ, Ankara, 06230, Turkey (Türkiye)
Institute of Science Tokyo Hospital
RECRUITING

Bunkyo-ku, Tokyo, 113-8519, Japan
Medical Center Artmed
RECRUITING

Plovdiv, 4000, Bulgaria
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji
NOT_YET_RECRUITING

Warsaw, Masovian Voivodeship, 02-637, Poland
National Taiwan University Hospital
NOT_YET_RECRUITING

Taipei, 10002, Taiwan
Nerve & Muscle Center of Texas
RECRUITING

Houston, Texas, 77030, United States
Nippon Medical School Hospital
RECRUITING

Bunkyo-ku, Tokyo, 113-8603, Japan
Nova Reuma Domyslawska i Rusilowicz Spolka Partnerska Lekarza Reumatologa i Fizjoterapeuty
RECRUITING

Bialystok, Podlaskie Voivodeship, 15-707, Poland
Peking Union Medical College Hospital
RECRUITING

Beijing, 100730, China
Renji Hospital Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200001, China
Renji Hospital Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Shanghai Municipality, 200127, China
Rheumatology & Pulmonary Clinic
RECRUITING

Beckley, West Virginia, 25801, United States
Sheba Medical Center
RECRUITING

Ramat Gan, Central District, 5262100, Israel
The Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
The Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.